PIK3CD and B-cell chronic lymphocytic leukemia: The activity of CAL-101 and other p110δ-selective inhibitors have been studied in cell lines and patient cells from different B-cell malignancies including CLL, MM, diffuse large B-cell lymphoma (DLBCL), and HL (Herman et al., 2010; Ikeda et al., 2010; Hoellenriegel et al., 2011; Lannutti et al., 2011; Meadows et al., 2012) (Table 2).